Convection-Enhanced Intraparenchymal Delivery of Drugs to the Brain

Aetna considers convection-enhanced intraparenchymal delivery of drugs to the brain experimental/investigational and does not cover it for any indications, including primary brain malignancies (C71.0–C71.9), secondary brain neoplasms (C79.31, C79.49), Alzheimer’s disease (G30.0–G30.9), or epilepsy (G40.001–G40.909). Coverage is excluded because safety and effectiveness have not been established, and no approved clinical indications or coverage requirements are provided.

"None — Aetna considers convection-enhanced delivery of drugs into brain parenchyma experimental and investigational because the safety and effectiveness of this approach has not been established."

Sign up to see full coverage criteria, indications, and limitations.